Finance

Lists
Why is MANKIND down ၃.၀၇%?
Dive Deeper
MANKIND:NSE
Mankind Pharma Ltd
၂,၂၇၅.၅၀ ₹
-၃.၀၇%
(-၇၂.၁၀) 1D
အောက် ၁၆, GMT+၅:၃၀ ၁၅:၃၀:၀၀  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for MANKIND...
Open
၂,၃၄၉.၉၀ ₹
High
၂,၃၅၄.၄၀ ₹
Low
၂,၂၆၈.၇၀ ₹
Mkt. cap
ဋေ ၉.၃၇ သ
Avg. vol.
၄.၈၄ သိန်း
Volume
၈.၉၀ သိန်း
P/E ratio
၄၆.၀၄
52-wk high
၂,၆၄၂.၀၀ ₹
52-wk low
၁,၉၀၉.၇၀ ₹
EPS
၄၉.၄၂ ₹
No. of employees
၂ သောင်း
Open
၂,၃၄၉.၉၀ ₹
High
၂,၃၅၄.၄၀ ₹
Low
၂,၂၆၈.၇၀ ₹
Mkt. cap
ဋေ ၉.၃၇ သ
Avg. vol.
၄.၈၄ သိန်း
Volume
၈.၉၀ သိန်း
P/E ratio
၄၆.၀၄
52-wk high
၂,၆၄၂.၀၀ ₹
52-wk low
၁,၉၀၉.၇၀ ₹
EPS
၄၉.၄၂ ₹
No. of employees
၂ သောင်း
News stories
From web sources and news partners
www.foreignpolicyjournal.com
www.foreignpolicyjournal.com
·
ပြီးခဲ့သည့် ၆ မိနစ်
Super Micro Computer (NASDAQ: SMCI) Signals Were Visible Before Its Stock 45% Rally
AskTraders.com
AskTraders.com
·
ပြီးခဲ့သည့် ၁ နာရီ
S&P 500 Can Absorb Fed Hikes, Says UBS CIO After Hot US Inflation
Yahoo Finance
Yahoo Finance
·
ပြီးခဲ့သည့် ၁၀ နာရီ
Michael Burry Warns of a Stock Market ‘Supervolcano’
AOL.com
AOL.com
·
ပြီးခဲ့သည့် ၆ နာရီ
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
Profile
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
About Mankind Pharma Ltd
CEORajeev Juneja | Sheetal Arora
Employees၂.၀၅ သောင်း
Founded၁၉၉၁
Headquarters-
Sector-
Next call ၈ ရက်အတွင်း
အောက် ၂၆ တနင်္လာ, ၁၄:၃၀
Fiscal period
Q2 2027
- / ၁၄.၇၇ ₹
Revenue / Est. (INR)
- / ဋေ ၄.၁၇ ထ
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
ဋေ ၃.၇၀ ထ
ဋေ ၃.၅၇ ထ
ဋေ ၃.၄၄ ထ
ဋေ ၄.၀၃ ထ
Cost of goods sold
ဋေ ၁.၀၆ ထ
၉၇၇.၉၉ ဋေ
ဋေ ၁.၁၇ ထ
ဋေ ၁.၁၀ ထ
Cost of revenue
ဋေ ၁.၀၆ ထ
၉၇၇.၉၉ ဋေ
ဋေ ၁.၁၇ ထ
ဋေ ၁.၁၀ ထ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၈၂၅.၁၈ ဋေ
၈၂၃.၇၁ ဋေ
ဋေ ၁.၅၈ ထ
၉၁၃.၅၀ ဋေ
Operating expense
ဋေ ၁.၉၄ ထ
ဋေ ၁.၈၉ ထ
ဋေ ၁.၄၈ ထ
ဋေ ၂.၁၀ ထ
Total operating expenses
ဋေ ၃.၀၀ ထ
ဋေ ၂.၈၇ ထ
ဋေ ၂.၆၅ ထ
ဋေ ၃.၂၀ ထ
Operating income
၆၉၉.၅၁ ဋေ
၆၉၆.၈၃ ဋေ
၇၉၄.၆၈ ဋေ
၈၃၀.၄၉ ဋေ
Other non operating income
၉၁.၈၇ ကုဋေ
၇၂.၇၅ ကုဋေ
-၂၃၁.၀၅ ဋေ
၄၅.၀၀ ကုဋေ
EBT including unusual items
၆၂၄.၀၂ ဋေ
၅၀၉.၀၀ ဋေ
၆၅၉.၁၇ ဋေ
၇၆၉.၄၅ ဋေ
EBT excluding unusual items
၆၂၄.၀၂ ဋေ
၆၁၅.၅၉ ဋေ
၅၅၈.၈၁ ဋေ
၇၆၉.၄၅ ဋေ
Income tax expense
၁၀၃.၈၄ ဋေ
၉၅.၁၂ ကုဋေ
၉၉.၇၅ ကုဋေ
၁၉၅.၃၆ ဋေ
Effective tax rate
၁၆.၆၄%
၁၈.၆၉%
၁၅.၁၃%
၂၅.၃၉%
Other operating expenses
၈၈၈.၄၈ ဋေ
၈၄၆.၀၇ ဋေ
-၃၂၅.၇၈ ဋေ
၉၆၂.၆၃ ဋေ
Net income
၅၁၁.၅၁ ဋေ
၄၀၈.၇၅ ဋေ
၅၅၄.၃၅ ဋေ
၅၆၈.၀၆ ဋေ
Net profit margin
၁၃.၈၄%
၁၁.၄၆%
၁၆.၁၀%
၁၄.၀၉%
Earnings per share
၁၂.၃၈
၁၁.၉၉
၁၃.၈၉
၁၃.၇၄
Interest and investment income
-
-
၅၈.၀၅ ကုဋေ
-
Interest expense
-၁၆၉.၆၈ ဋေ
-၁၅၇.၂၀ ဋေ
-၁၃၅.၈၇ ဋေ
-၁၀၉.၉၈ ဋေ
Net interest expenses
-၁၆၉.၆၈ ဋေ
-၁၅၇.၂၀ ဋေ
-၇၇.၈၂ ကုဋေ
-၁၀၉.၉၈ ဋေ
Depreciation and amortization charges
၂၂၁.၈၂ ဋေ
၂၂၂.၆၀ ဋေ
၂၂၃.၀၈ ဋေ
၂၂၅.၇၀ ဋေ
EBITDA
၉၁၉.၇၆ ဋေ
၈၄၂.၄၉ ဋေ
၉၉၇.၄၂ ဋေ
ဋေ ၁.၀၃ ထ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google အက်ပ်များ